BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity With Manageable Tolerability Among Heavily Pretreated Patients With Squamous Cell Carcinoma Of The Head And Neck At The 2024 ESMO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
BioAtla presented promising Phase 2 trial data for ozuriftamab vedotin, showing a 32% overall response rate in heavily pretreated patients with squamous cell carcinoma of the head and neck. The treatment was well tolerated, and BioAtla plans to discuss a potential registrational trial with the FDA in 2024.
September 16, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioAtla's Phase 2 trial data for ozuriftamab vedotin shows promising results with a 32% ORR in SCCHN patients. The treatment was well tolerated, and the company plans to discuss a potential registrational trial with the FDA in 2024.
The positive Phase 2 trial results for ozuriftamab vedotin, including a 32% ORR and manageable tolerability, are significant for BioAtla. The potential for a registrational trial with the FDA in 2024 could lead to further advancements and approvals, positively impacting BioAtla's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100